{"id":"W4281683594","doi":"10.1200/jco.2022.40.16_suppl.9069","title":"Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with <i>ALK</i>+ advanced non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Crizotinib; Medicine; Internal medicine; ALK inhibitor; Clinical endpoint; Progression-free survival; Lung cancer; Randomization; Oncology; Chemotherapy; Randomized controlled trial; Gastroenterology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00166177,0.000575788,0.001344698,0.0002579636,0.0003302538,0.0006925559,0.0004039295,0.0007219824,0.002935726],"category_scores_gemma":[0.001210551,0.0002868368,0.00140895,0.0002881459,0.0004990123,0.0004952311,0.0004048948,0.002186471,0.0004465733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008486353,"about_ca_system_score_gemma":0.001062887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009326715,"about_ca_topic_score_gemma":0.00347853,"domain_scores_codex":[0.9995282,0.0002400157,0.0000293894,0.00007923388,0.0000546629,0.00006844902],"domain_scores_gemma":[0.9992181,0.0001445973,0.0002111708,0.00005033476,0.00004595326,0.0003298125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9073313,0.007201698,0.00818623,0.0005619273,0.0009371078,0.0001187693,0.0001455594,0.001062152,0.01071972,0.00009929243,0.003820274,0.05981598],"study_design_scores_gemma":[0.6210484,0.3175569,0.0515324,0.00007319705,0.001318099,0.0003561148,0.00003991818,0.001353701,0.002699971,0.0001896292,0.003791942,0.00003975096],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936685,0.002276695,0.000186929,0.0003268314,0.00009223435,0.0008844024,0.0008970002,0.00003212001,0.001635208],"genre_scores_gemma":[0.9944193,0.0009724048,0.0005260537,0.000621359,0.0001493915,0.00066718,0.0018765,0.000009691705,0.0007581656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002935726,"threshold_uncertainty_score":0.009820998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05485920621376665,"score_gpt":0.4693757843956529,"score_spread":0.4145165781818862,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}